Ny styrka Færre tabletter å innta for pasienter som behandles med Braftovi® + Mektovi® Doseringen av BRAFTOVI® er uforandret BRAFTOVI® (enkorafenib) i kombinasjon med MEKTOVI® (binimetinib) er indisert til behandling av voksne pasienter med: inoperabelt eller metastaserende melanom med…
Research summary edited by Pierre Fabre With a median follow-up duration of 100 months, the seven-year analysis from the COLUMBUS trial’s part 1 confirms the long-term, sustained efficacy and known safety profile of encorafenib + binimetinib in patients with BRAFV600-mutant…
In Sweden adjuvant systemic therapies for patients following surgical treatment of high-risk melanoma was introduced as a recommendation in the national guidelines in the end of 2018. Treatment recommendations are based on the AJCC 8th edition staging system, where unfortunately…
In January 2023, Pierre Fabre arranged a national symposium in Gothenburg, Sweden, focusing on the latest insights into the treatment of BRAF-mutant melanoma. The symposium, moderated by Professor Lars Ny, gathered oncologists, surgeons and pathologists involved in diagnosing and treating…
The Nordic melanoma meeting was held October 11–13 in Reykjavik and brought together Nordic and international clinicians and researchers. Pierre Fabre’s oncology team was on site and caught up with Professor Roger Olofsson Bagge and Professor Lars Ny to discuss…
Molecular targeted therapies and immune checkpoint inhibitors have changed the treatment landscape for BRAFV600E-mutant metastatic colorectal cancer (mCRC). This review is based on a scientific literature search and analysis by a European expert panel. It provides consensus statements on management…
The introduction of immune checkpoint inhibitors (ICI) such as the cytotoxic T-lymphocyte-associated antigen 4 inhibitors (CTLA-4) and programmed death 1 inhibitors (PD-1), as well as targeted therapies (TT) exemplified by BRAF and MEK inhibitors have significantly altered the treatment paradigm…
Though metastatic colorectal cancer (mCRC) remains a devastating disease, promising progress has been made in the field of mCRC research. We interviewed Prof. Bengt Glimelius, from the University of Uppsala, Sweden, about the recent developments in mCRC treatment and insights…
Research summary edited by Pierre Fabre from: COLUMBUS 5-year update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. COLUMBUS study: Five-year follow up on efficacy and safety of…